Advertisement
Advertisement
MXCT
MaxCyte, Inc. Common Stock
1.18
USDSponsored
+0.07
+6.31%
Aug 07, 15:58 UTC -4
Closed
Pre-Market
1.18
0.00
0.00%
MXCT Earnings Reports
Positive Surprise Ratio
MXCT beat 17 of 20 last estimates.
85%
Next Report
In 2 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$6.60M
/-$0.09
Implied change from Q1 26 (Revenue/ EPS)
-31.56%
/+125.00%
Implied change from Q2 25 (Revenue/ EPS)
-22.36%
/-25.00%
MaxCyte, Inc. Common Stock earnings per share and revenue
On May 12, 2026, MXCT reported earnings of -0.04 USD per share (EPS) for Q1 26, beating the estimate of -0.08 USD, resulting in a 50.98% surprise. Revenue reached 9.65 million, compared to an expected 7.44 million, with a 29.64% difference. The market reacted with a +24.06% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.09 USD, with revenue projected to reach 6.60 million USD, implying an increase of 125.00% EPS, and decrease of -31.56% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were MaxCyte, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, MaxCyte, Inc. Common Stock reported EPS of -$0.04, beating estimates by 50.98%, and revenue of $9.65M, 29.64% above expectations.
How did the market react to MaxCyte, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 24.06%, changed from $0.82 before the earnings release to $1.02 the day after.
When is MaxCyte, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for MaxCyte, Inc. Common Stock's next earnings report?
Based on --
analysts, MaxCyte, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $6.60M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement